ESSA Pharma Statistics
Share Statistics
ESSA Pharma has 44.37M shares outstanding. The number of shares has increased by 0.61% in one year.
| Shares Outstanding | 44.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 43.38M |
| Failed to Deliver (FTD) Shares | 10.71K |
| FTD / Avg. Volume | 1.22% |
Short Selling Information
The latest short interest is 1.15M, so 2.59% of the outstanding shares have been sold short.
| Short Interest | 1.15M |
| Short % of Shares Out | 2.59% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 30.53 |
Valuation Ratios
The PE ratio is -5.13 and the forward PE ratio is -3.72.
| PE Ratio | -5.13 |
| Forward PE | -3.72 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.94 |
| P/FCF Ratio | -6.89 |
| PEG Ratio | n/a |
Enterprise Valuation
ESSA Pharma Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 42.57, with a Debt / Equity ratio of 0.
| Current Ratio | 42.57 |
| Quick Ratio | 42.57 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -4628.94 |
Financial Efficiency
Return on equity (ROE) is -0.18% and return on capital (ROIC) is -22.06%.
| Return on Equity (ROE) | -0.18% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | -22.06% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -531.65K |
| Employee Count | 50 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1.60K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -73.35% in the last 52 weeks. The beta is 1.84, so ESSA Pharma 's price volatility has been higher than the market average.
| Beta | 1.84 |
| 52-Week Price Change | -73.35% |
| 50-Day Moving Average | 3.35 |
| 200-Day Moving Average | 5.59 |
| Relative Strength Index (RSI) | 24.35 |
| Average Volume (20 Days) | 877.77K |
Income Statement
In the last 12 months, ESSA Pharma had revenue of $0 and earned -$26.58M in profits. Earnings per share was $-0.6.
| Revenue | 0 |
| Gross Profit | -118.49K |
| Operating Income | -32.13M |
| Net Income | -26.58M |
| EBITDA | -26.46M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has $33.70M in cash and $80.33K in debt, giving a net cash position of $33.62M.
| Cash & Cash Equivalents | 33.70M |
| Total Debt | 80.33K |
| Net Cash | 33.62M |
| Retained Earnings | -179.46M |
| Total Assets | 132.67M |
| Working Capital | 128.52M |
Cash Flow
In the last 12 months, operating cash flow was -$19.78M and capital expenditures $0, giving a free cash flow of -$19.78M.
| Operating Cash Flow | -19.78M |
| Capital Expenditures | 0 |
| Free Cash Flow | -19.78M |
| FCF Per Share | -0.45 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
EPIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -36.14% |
| FCF Yield | -26.86% |
Analyst Forecast
The average price target for EPIX is $2, which is 20.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | 20.5% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Apr 25, 2018. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 25, 2018 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | 9.82 |
| Piotroski F-Score | 1 |